UBS Raises PT on Iovance Biotherapeutics (IOVA)

Core Viewpoint - Iovance Biotherapeutics, Inc. has received a price target increase from UBS analyst David Dai, reflecting positive developments in its financial performance, particularly in Q4 2025, despite uncertainties regarding the acceleration of its product AMTAGVI [1][2]. Financial Performance - Iovance reported a quarterly revenue of $86.77 million for fiscal Q4 2025, marking a year-over-year growth of 17.74% and exceeding estimates by $5.76 million [2]. - The company's full-year product revenue reached $264 million, driven by a significant 112% year-over-year increase in AMTAGVI revenue [3]. Product Development - The growth in revenue is attributed to the commercialization of AMTAGVI for advanced melanoma, which has seen increased uptake in both academic and community treatment centers [3]. - Management indicated that guidance for fiscal 2026 revenue will be provided soon, suggesting ongoing strategic planning and potential for future growth [4]. Analyst Insights - UBS has maintained a Neutral rating on Iovance's stock while raising the price target from $2 to $4, indicating cautious optimism about the company's future performance [1][2].